International prognostic score for asymptomatic early-stage
chronic lymphocytic leukemia

J 2020

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING et. al.

Basic information

Original name

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Authors

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK (203 Czech Republic, belonging to the institution), F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK and D. ROSSI (guarantor)

Edition

Blood, Washington DC, USA, American Society of Hematology, 2020, 0006-4971

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 22.113

RIV identification code

RIV/00216224:14110/20:00117894

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1182/blood.2019003453

UT WoS

000535968000010

Keywords in English

chronic lymphocytic leukemia; prognostic score

Abstract

V originále

Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 x 10(9)/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

NV19-03-00091, research and development project

Name: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby

Investor: Ministry of Health of the CR

Citovat

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK, F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ, C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ, F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK and D. ROSSI. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. Washington DC, USA: American Society of Hematology, 2020, vol. 135, No 21, p. 1859-1869. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood.2019003453.

@article{1730622,
   author = {Condoluci, A. and di Bergamo, L. T. and Langerbeins, P. and Hoechstetter, M. A. and Herling, C. D. and De Paoli, L. and Delgado, J. and Rabe, K. G. and Gentile, M. and Doubek, Michael and Mauro, F. R. and Chiodin, G. and Mattsson, M. and Bahlo, J. and Cutrona, G. and Kotašková, Jana and Deambrogi, C. and Smedby, K. E. and Spina, V. and Bruscaggin, A. and Wu, W. and Moia, R. and Bianchi, E. and Gerber, B. and Zucca, E. and Gillessen, S. and Ghielmini, M. and Cavalli, F. and Stussi, G. and Hess, M. A. and Baumann, T. S. and Neri, A. and Ferrarini, M. and Rosenquist, R. and Forconi, F. and Foa, R. and Pospíšilová, Šárka and Morabito, F. and Stilgenbauer, S. and Dohner, H. and Parikh, S. A. and Wierda, W. G. and Montserrat, E. and Gaidano, G. and Hallek, M. and Rossi, D.},
   article_location = {Washington DC, USA},
   article_number = {21},
   doi = {http://dx.doi.org/10.1182/blood.2019003453},
   keywords = {chronic lymphocytic leukemia; prognostic score},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia},
   url = {https://watermark.silverchair.com/bloodbld2019003453.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-wwggPoBgkqhkiG9w0BBwagggPZMIID1QIBADCCA84GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMXRXeaAY25mjozM5SAgEQgIIDnxhMmZAU5cNiFCUDj79Os54hBBpUZ00qooo},
   volume = {135},
   year = {2020}
}

TY  - JOUR
ID  - 1730622
AU  - Condoluci, A. - di Bergamo, L. T. - Langerbeins, P. - Hoechstetter, M. A. - Herling, C. D. - De Paoli, L. - Delgado, J. - Rabe, K. G. - Gentile, M. - Doubek, Michael - Mauro, F. R. - Chiodin, G. - Mattsson, M. - Bahlo, J. - Cutrona, G. - Kotašková, Jana - Deambrogi, C. - Smedby, K. E. - Spina, V. - Bruscaggin, A. - Wu, W. - Moia, R. - Bianchi, E. - Gerber, B. - Zucca, E. - Gillessen, S. - Ghielmini, M. - Cavalli, F. - Stussi, G. - Hess, M. A. - Baumann, T. S. - Neri, A. - Ferrarini, M. - Rosenquist, R. - Forconi, F. - Foa, R. - Pospíšilová, Šárka - Morabito, F. - Stilgenbauer, S. - Dohner, H. - Parikh, S. A. - Wierda, W. G. - Montserrat, E. - Gaidano, G. - Hallek, M. - Rossi, D.
PY  - 2020
TI  - International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
JF  - Blood
VL  - 135
IS  - 21
SP  - 1859-1869
EP  - 1859-1869
PB  - American Society of Hematology
SN  - 00064971
KW  - chronic lymphocytic leukemia
KW  - prognostic score
UR  - https://watermark.silverchair.com/bloodbld2019003453.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-wwggPoBgkqhkiG9w0BBwagggPZMIID1QIBADCCA84GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMXRXeaAY25mjozM5SAgEQgIIDnxhMmZAU5cNiFCUDj79Os54hBBpUZ00qooo
L2  - https://watermark.silverchair.com/bloodbld2019003453.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-wwggPoBgkqhkiG9w0BBwagggPZMIID1QIBADCCA84GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMXRXeaAY25mjozM5SAgEQgIIDnxhMmZAU5cNiFCUDj79Os54hBBpUZ00qooo
N2  - Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 x 10(9)/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.
ER  -

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK, F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ, C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ, F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK and D. ROSSI. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2020, vol.~135, No~21, p.~1859-1869. ISSN~0006-4971. Available from: https://dx.doi.org/10.1182/blood.2019003453.

Detailed Information on Publication Record